Biotech | October 11, 2021
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Research collaboration covers multiple antibody research programs
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Inclacumab was generally well tolerated in THRIVE-131
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
